A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.

about

A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.

Item

http://www.wikidata.org/entity/Q38691539

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A Poisson approach to the vali ...... al patient data meta-analyses.

@en

type

Item

label

A Poisson approach to the vali ...... al patient data meta-analyses.

@en

prefLabel

A Poisson approach to the vali ...... al patient data meta-analyses.

@en

P1476

A Poisson approach to the vali ...... al patient data meta-analyses.

@en

P2093

Marc Buyse

http://www.w3.org/2001/XMLSchema#string

Xavier Paoletti

http://www.w3.org/2001/XMLSchema#string

P2860

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis

Log-normal frailty models fitted as Poisson generalized linear mixed models.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Individual patient data meta-analysis of survival data using Poisson regression models.

The impact of heterogeneity in individual frailty on the dynamics of mortality.

Advanced methods in meta-analysis: multivariate approach and meta-regression.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

P304

962280217718582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0962280217718582

http://www.w3.org/2001/XMLSchema#string

P50

Federico Rotolo

Stefan Michiels

Tomasz Burzykowski

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28681681

http://www.w3.org/2001/XMLSchema#string

P921

meta-analysis